Clinical trial NCT04049877: Retrospective and Prospective Disease Progression and Quality of Life in XLH
Official title: Retrospective and Prospective Disease Progression and Quality of Life in X-linked Hypophosphatemia (XLH)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: X-linked Hypophosphatemia (XLH)
Lead sponsor: Medialis Ltd.
Sponsor class: INDUSTRY
First posted: 2019-08-08
Enrollment: 11
Sex: ALL
Minimum age (years): 28
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with XLH

Brief summary: There is limited empirical data documenting disease progression and impact on quality of life for patients with X-linked hypophosphatemia (XLH). This study seeks to investigate the impact of XLH in adults living in the UK retrospectively and prospectively over a 12 month period, using qualitative interviews, SEIQoL-DW, EQ-5D-5L, SF36 quality of life tools.

XLH is a rare, genetic, chronically debilitating and deforming condition (www.nice.org.uk/guidance/HST8). XLH is characterised by renal phosphate wasting, hypophosphatemia and defective bone mineralisation. The incidence of XLH is reported to be between 1:20,000 and 1:25,000 live births. In the UK, it is estimated that there are around 250 paediatric XLH patients and around 2,500 adult XLH patients (Delmestri,et al \[Unpublished report\]2018). The clinical phenotype of XLH is varied amongst patients, even among affected members of the same family. This can range from no signs or symptoms, slow growth in children, short stature, bone abnormalities that can affect movement and result in pain, bowed legs and knocked knees (where lower legs are positioned at an outward angle), tooth abscesses and excessive dental caries and hearing loss (adult patients only).

This study will recruit 36 adults living with XLH, who are aged 28 years or over and living in the UK. The study will be advertised by the Sponsor and funder Medialis Ltd and via the patient organisation Metabolic Support UK. All study activities will take place via tele-visits and online questionnaires. The study will last approximately 2 years, allowing for one-year recruitment and a further 12 months to conduct all study visits.


Eligibility criteria: Inclusion Criteria:

* • Participant has a diagnosis of XLH

  * Participant is aged 28 years and above.
  * Participant is capable of providing informed consent
  * Participant is able to read and converse in English
  * Participant is able to comply with the study schedule (5 tele-visits over a 12-month period)

Exclusion Criteria:

* • Participant does not have a diagnosis of XLH

  * Participant is aged under 28 years
  * Participant is not capable of giving informed consent
  * Participant is unable to read and converse in English
  * Participant is unable to comply the with study schedule (5 tele-visits over a 12-month period)

Primary outcomes:
measure: Schedule for the Evaluation of Individual Quality of Life Direct Weight (SEIQoL-DW)
timeFrame: 12 months
measure: Disease progression in adults living with XLH
timeFrame: 12 months
Secondary outcomes:
measure: EQ- 5D-5L
timeFrame: 12 months
measure: SF36
timeFrame: 12 months
Other outcomes:
Locations:
city: Oxford
country: United Kingdom
facility: Medialis
Study officials:
References: